{"id":758024,"date":"2023-05-11T12:36:04","date_gmt":"2023-05-11T16:36:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/"},"modified":"2023-05-11T12:36:04","modified_gmt":"2023-05-11T16:36:04","slug":"adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/","title":{"rendered":"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress"},"content":{"rendered":"

<\/p>\n

ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress<\/b><\/p>\n

\n\u00a0Poster presentation will highlight durable, long-term responses in relapsed\/refractory DLBCL patients treated with ZYNLONTA<\/i>\u00ae<\/p>\n

LAUSANNE, Switzerland–(BUSINESS WIRE<\/a>)–
\nADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023.<\/p>\n

\n\u201cWe are encouraged by the latest developments from our pivotal LOTIS-2 trial, which further validate the long\u2010term disease control of ZYNLONTA in heavily pretreated patients with DLBCL,\u201d said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. \u201cZYNLONTA has substantial single-agent antitumor activity and produces durable responses with an acceptable safety profile. We look forward to sharing our new data with the hematology community at EHA2023.\u201d<\/p>\n

\nDetails of ADC Therapeutics\u2019 poster presentation are as follows:<\/p>\n

\nLong-Term Responses with Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study In Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma
\n
Session: Aggressive Non-Hodgkin lymphoma \u2013 Clinical
\n
Session Date and Time: Friday, June 9, 2023, 18:00 \u2013 19:00 CEST \/\/ 12:00 pm \u2013 1:00 pm EDT
\n
Location: Poster area
\n
Location Time: Poster area opens at 9:00 am CEST
\n
Presenting Author: Paolo F. Caimi, MD, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
\n
Abstract Code: P1132<\/p>\n

About ZYNLONTA<\/b>\u00ae (loncastuximab tesirine-lpyl)<\/b><\/p>\n

\nZYNLONTA\u00ae is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.<\/p>\n

\nThe U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r\/r) large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double\/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at www.ZYNLONTA.com<\/a>.<\/p>\n

\nZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.<\/p>\n

About ADC Therapeutics<\/b><\/p>\n

\nADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.<\/p>\n

\nADC Therapeutics\u2019 CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.<\/p>\n

\nADC Therapeutics is based in Lausanne (Biop\u00f4le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https:\/\/adctherapeutics.com\/<\/a> and follow the Company on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\nZYNLONTA\u00ae is a registered trademark of ADC Therapeutics SA.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the benefits, if any, of the updated clinical data from the LOTIS-2 study of ZYNLONTA\u00ae to be presented at EHA 2023; the success of the Company\u2019s updated corporate strategy including operating efficiencies, capital deployment and portfolio prioritization; the Company\u2019s ability to achieve the 2023 net product sales guidance for ZYNLONTA\u00ae and the decrease in total operating expenses for 2023 and 2024, the expected cash runway into the middle of 2025, the effectiveness of the new commercial go-to-market strategy and the Company\u2019s ability to continue to commercialize ZYNLONTA\u00ae in the United States and future revenue from the same; Swedish Orphan Biovitrum AB (Sobi\u00ae) ability to successfully commercialize ZYNLONTA\u00ae in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; our strategic partners\u2019, including Mitsubishi Tanabe Pharma Corporation and Overland Pharmaceuticals, ability to obtain regulatory approval for ZYNLONTA\u00ae in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the Company\u2019s ability to market its products in compliance with applicable laws and regulations; the Company\u2019s expectations regarding the impact of the Infrastructure Investment and Jobs Act; the timing and results of the Company\u2019s or its partners\u2019 research projects or clinical trials including LOTIS 5, 7 and 9, ADCT 901, 601 and 602, the timing and outcome of regulatory submissions and actions by the FDA or other regulatory agencies with respect to the Company\u2019s products or product candidates; projected revenue and expenses; the Company\u2019s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company\u2019s activities by such indebtedness, the ability to repay such indebtedness and the significant cash required to service such indebtedness; the Company\u2019s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as \u201cmay\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201cwould\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cestimate\u201d, \u201cpredict\u201d, \u201cpotential\u201d, \u201cseem\u201d, \u201cseek\u201d, \u201cfuture\u201d, \u201ccontinue\u201d, or \u201cappear\u201d or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the \u201cRisk Factors\u201d section of the Company’s Annual Report on Form 20-F and in the Company’s other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. The Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230511005589\/en\/<\/a><\/span><\/p>\n

Investors
\n<\/b>
Eugenia Litz
\n
ADC Therapeutics
\n
Eugenia.Litz@adctherapeutics.com
\n<\/a>
+44 7879 627205<\/p>\n

Amanda Loshbaugh
\n
ADC Therapeutics
\n
amanda.loshbaugh@adctherapeutics.com
\n<\/a>
+1 917-288-7023<\/p>\n

Media
\n<\/b>
Mary Ann Ondish
\n
ADC Therapeutics
\n
maryann.ondish@adctherapeutics.com
\n<\/a>
+1 914-552-4625<\/p>\n

KEYWORDS:<\/b> Switzerland Europe Germany<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Science Research Clinical Trials Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress \u00a0Poster presentation will highlight durable, long-term responses in relapsed\/refractory DLBCL patients treated with ZYNLONTA\u00ae LAUSANNE, Switzerland–(BUSINESS WIRE)– ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023. \u201cWe are encouraged by the latest developments from our pivotal LOTIS-2 trial, which further validate the long\u2010term disease control of ZYNLONTA in heavily pretreated patients with DLBCL,\u201d said Mohamed … <\/p>\n

Continue reading “ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758024","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress \u00a0Poster presentation will highlight durable, long-term responses in relapsed\/refractory DLBCL patients treated with ZYNLONTA\u00ae LAUSANNE, Switzerland–(BUSINESS WIRE)– ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023. \u201cWe are encouraged by the latest developments from our pivotal LOTIS-2 trial, which further validate the long\u2010term disease control of ZYNLONTA in heavily pretreated patients with DLBCL,\u201d said Mohamed … Continue reading "ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-11T16:36:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress\",\"datePublished\":\"2023-05-11T16:36:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/\"},\"wordCount\":1264,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/\",\"name\":\"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-11T16:36:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/","og_locale":"en_US","og_type":"article","og_title":"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk","og_description":"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress \u00a0Poster presentation will highlight durable, long-term responses in relapsed\/refractory DLBCL patients treated with ZYNLONTA\u00ae LAUSANNE, Switzerland–(BUSINESS WIRE)– ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023. \u201cWe are encouraged by the latest developments from our pivotal LOTIS-2 trial, which further validate the long\u2010term disease control of ZYNLONTA in heavily pretreated patients with DLBCL,\u201d said Mohamed … Continue reading \"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-11T16:36:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress","datePublished":"2023-05-11T16:36:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/"},"wordCount":1264,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/","name":"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-11T16:36:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230511005589r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-updated-results-from-lotis-2-trial-to-be-presented-at-the-european-hematology-association-2023-hybrid-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758024"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758024\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}